- Home
- NXP vs TERN Comparison
NXP vs TERN Comparison
Compare NXP & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- TERN
- Stock Information
- Founded
- NXP 1992
- TERN 2017
- Country
- NXP United States
- TERN United States
- Employees
- NXP N/A
- TERN N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- NXP Finance
- TERN Health Care
- Exchange
- NXP Nasdaq
- TERN Nasdaq
- Market Cap
- NXP 744.2M
- TERN 710.6M
- IPO Year
- NXP N/A
- TERN 2021
- Fundamental
- Price
- NXP $14.32
- TERN $28.67
- Analyst Decision
- NXP
- TERN Buy
- Analyst Count
- NXP 0
- TERN 11
- Target Price
- NXP N/A
- TERN $23.59
- AVG Volume (30 Days)
- NXP 70.0K
- TERN 5.6M
- Earning Date
- NXP 01-01-0001
- TERN 11-10-2025
- Dividend Yield
- NXP 4.04%
- TERN N/A
- EPS Growth
- NXP N/A
- TERN N/A
- EPS
- NXP 0.54
- TERN N/A
- Revenue
- NXP N/A
- TERN N/A
- Revenue This Year
- NXP N/A
- TERN N/A
- Revenue Next Year
- NXP N/A
- TERN N/A
- P/E Ratio
- NXP $26.81
- TERN N/A
- Revenue Growth
- NXP N/A
- TERN N/A
- 52 Week Low
- NXP $12.91
- TERN $1.87
- 52 Week High
- NXP $14.89
- TERN $29.38
- Technical
- Relative Strength Index (RSI)
- NXP 44.41
- TERN 84.01
- Support Level
- NXP $14.20
- TERN $25.31
- Resistance Level
- NXP $14.49
- TERN $28.49
- Average True Range (ATR)
- NXP 0.18
- TERN 1.97
- MACD
- NXP -0.01
- TERN 0.60
- Stochastic Oscillator
- NXP 33.34
- TERN 99.45
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.